EGFR and pneumonitis: In addition, we found that consolidation chemotherapy did not have a significant contribution to OS; EGFR mutation status did not have a significant impact on PFS in patients who underwent CRT; the 3‐year OS rate was better with cisplatin‐based regimens; and the incidence of pneumonitis was lowest with cisplatin + vinorelbine.